{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:27Z","timestamp":1792785867190,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Barts CVCTU"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Current guidelines recommend the use of vitamin K antagonist (VKA) for up to 3\u20136\u2009months for treatment of left ventricular (LV) thrombus post-acute myocardial infarction (AMI). However, based on evidence supporting non-inferiority of novel oral anticoagulants (NOAC) compared to VKA for other indications such as deep vein thrombosis, pulmonary embolism (PE), and thromboembolic prevention in atrial fibrillation, NOACs are being increasingly used off licence for the treatment of LV thrombus post-AMI. In this study, we investigated the safety and effect of NOACs compared to VKA on LV thrombus resolution in patients presenting with AMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This was an observational study of 2328 consecutive patients undergoing coronary angiography \u00b1 percutaneous coronary intervention (PCI) for AMI between May 2015 and December 2018, at a UK cardiac centre. Patients\u2019 details were collected from the hospital electronic database. The primary endpoint was rate of LV thrombus resolution with bleeding rates a secondary outcome. Left ventricular thrombus was diagnosed in 101 (4.3%) patients. Sixty patients (59.4%) were started on VKA and 41 patients (40.6%) on NOAC therapy (rivaroxaban: 58.5%, apixaban: 36.5%, and edoxaban: 5.0%). Both groups were well matched in terms of baseline characteristics including age, previous cardiac history (previous myocardial infarction, PCI, coronary artery bypass grafting), and cardiovascular risk factors (hypertension, diabetes, hypercholesterolaemia). Over the follow-up period (median 2.2\u2009years), overall rates of LV thrombus resolution were 86.1%. There was greater and earlier LV thrombus resolution in the NOAC group compared to patients treated with warfarin (82% vs. 64.4%, P\u2009=\u20090.0018, at 1\u2009year), which persisted after adjusting for baseline variables (odds ratio 1.8, 95% confidence interval 1.2\u20132.9). Major bleeding events during the follow-up period were lower in the NOAC group, compared with VKA group (0% vs. 6.7%, P\u2009=\u20090.030) with no difference in rates of systemic thromboembolism (5% vs. 2.4%, P\u2009=\u20090.388).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data suggest improved thrombus resolution in post-acute coronary syndrome (ACS) LV thrombosis in patients treated with NOACs compared to VKAs. This improvement in thrombus resolution was accompanied with a better safety profile for NOAC patients vs. VKA-treated patients. Thus, provides data to support a randomized trial to answer this question.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaa096","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T07:26:41Z","timestamp":1595575601000},"page":"398-404","source":"Crossref","is-referenced-by-count":105,"title":["The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction"],"prefix":"10.1093","volume":"7","author":[{"given":"Daniel A","family":"Jones","sequence":"first","affiliation":[{"name":"Barts Interventional Group, Interventional Cardiology, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London EC1A 7BE, UK"},{"name":"Charterhouse Square Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London EC1A 7BE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momin A","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"Barts Interventional Group, Interventional Cardiology, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London EC1A 7BE, UK"},{"name":"Charterhouse Square Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadeer","family":"Fhadil","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London EC1A 7BE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-5055","authenticated-orcid":false,"given":"Krishnaraj S","family":"Rathod","sequence":"additional","affiliation":[{"name":"Barts Interventional Group, Interventional Cardiology, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London EC1A 7BE, UK"},{"name":"Charterhouse Square Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Guttmann","sequence":"additional","affiliation":[{"name":"Barts Interventional Group, Interventional Cardiology, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London EC1A 7BE, UK"},{"name":"Charterhouse Square Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Knight","sequence":"additional","affiliation":[{"name":"Barts Interventional Group, Interventional Cardiology, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London EC1A 7BE, UK"},{"name":"Charterhouse Square Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Timmis","sequence":"additional","affiliation":[{"name":"Barts Interventional Group, Interventional Cardiology, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London EC1A 7BE, UK"},{"name":"Charterhouse Square Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7707-2254","authenticated-orcid":false,"given":"Andreas","family":"Baumbach","sequence":"additional","affiliation":[{"name":"Barts Interventional Group, Interventional Cardiology, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London EC1A 7BE, UK"},{"name":"Charterhouse Square Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wragg","sequence":"additional","affiliation":[{"name":"Barts Interventional Group, Interventional Cardiology, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London EC1A 7BE, UK"},{"name":"Charterhouse Square Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-9653","authenticated-orcid":false,"given":"Anthony","family":"Mathur","sequence":"additional","affiliation":[{"name":"Barts Interventional Group, Interventional Cardiology, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London EC1A 7BE, UK"},{"name":"Charterhouse Square Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotiris","family":"Antoniou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London EC1A 7BE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"key":"2021092108265481400_pvaa096-B1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamacardio.2018.1086","article-title":"Left ventricular thrombus after acute myocardial infarction: screening, prevention, and treatment","volume":"3","author":"McCarthy","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2021092108265481400_pvaa096-B2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12968-018-0494-3","article-title":"Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a meta-analysis","volume":"20","author":"Bulluck","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"2021092108265481400_pvaa096-B3","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1016\/j.ejrad.2012.06.029","article-title":"Left ventricular thrombus formation after acute myocardial infarction as assessed by cardiovascular magnetic resonance imaging","volume":"81","author":"Delewi","year":"2012","journal-title":"Eur J Radiol"},{"key":"2021092108265481400_pvaa096-B4","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ijcard.2016.07.069","article-title":"Left ventricular thrombi after STEMI in the primary PCI era: a systematic review and meta-analysis","volume":"221","author":"Robinson","year":"2016","journal-title":"Int J Cardiol"},{"key":"2021092108265481400_pvaa096-B5","first-page":"100395","article-title":"Incidence and predictors of left ventricular thrombus formation following acute ST-segment elevation myocardial infarction: a serial cardiac MRI study","volume":"24","author":"Phan","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2021092108265481400_pvaa096-B6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ahj.2015.04.029","article-title":"Incidence, diagnostic methods, and evolution of left ventricular thrombus in patients with anterior myocardial infarction and low left ventricular ejection fraction: a prospective multicenter study","volume":"170","author":"Meurin","year":"2015","journal-title":"Am Heart J"},{"key":"2021092108265481400_pvaa096-B7","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jacc.2015.10.005","article-title":"2015 ACC\/AHA\/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction","volume":"67","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2021092108265481400_pvaa096-B8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2021092108265481400_pvaa096-B9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2021092108265481400_pvaa096-B10","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/ATVBAHA.117.306995","article-title":"Impact of non-vitamin K antagonist oral anticoagulants from a basic science perspective","volume":"37","author":"Hoffman","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2021092108265481400_pvaa096-B11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.amjmed.2018.12.036","article-title":"Net clinical benefit of non-vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation","volume":"132","author":"Patti","year":"2019","journal-title":"Am J Med"},{"key":"2021092108265481400_pvaa096-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40119-018-0107-0","article-title":"A review of the role of non-vitamin K oral anticoagulants in the acute and long-term treatment of venous thromboembolism","volume":"7","author":"Bromley","year":"2018","journal-title":"Cardiol Ther"},{"key":"2021092108265481400_pvaa096-B13","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.clinthera.2018.10.009","article-title":"A review of the efficacy and safety profiles of the novel oral anticoagulants in the treatment and prevention of venous thromboembolism","volume":"40","author":"Coulis","year":"2018","journal-title":"Clin Ther"},{"key":"2021092108265481400_pvaa096-B14","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"2021092108265481400_pvaa096-B15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamacardio.2020.0652","article-title":"Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi","volume":"5","author":"Robinson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2021092108265481400_pvaa096-B16","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2021092108265481400_pvaa096-B17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V","volume":"167","author":"White","year":"2007","journal-title":"Arch Intern Med"},{"key":"2021092108265481400_pvaa096-B18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"2021092108265481400_pvaa096-B19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1476-7120-4-20","article-title":"Incidence of post myocardial infarction left ventricular thrombus formation in the era of primary percutaneous intervention and glycoprotein IIb\/IIIa inhibitors. A prospective observational study","volume":"4","author":"Rehan","year":"2006","journal-title":"Cardiovasc Ultrasound"},{"key":"2021092108265481400_pvaa096-B20","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ahj.2009.03.020","article-title":"Incidence of early left ventricular thrombus after acute anterior wall myocardial infarction in the primary coronary intervention era","volume":"157","author":"Osherov","year":"2009","journal-title":"Am Heart J"},{"key":"2021092108265481400_pvaa096-B21","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.amjcard.2013.12.015","article-title":"Incidence and predictors of early left ventricular thrombus after ST-elevation myocardial infarction in the contemporary era of primary percutaneous coronary intervention","volume":"113","author":"Gianstefani","year":"2014","journal-title":"Am J Cardiol"},{"key":"2021092108265481400_pvaa096-B22","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1136\/heartjnl-2012-301962","article-title":"Left ventricular thrombus formation after acute myocardial infarction","volume":"98","author":"Delewi","year":"2012","journal-title":"Heart"},{"key":"2021092108265481400_pvaa096-B23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2008.03.041","article-title":"Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction","volume":"52","author":"Weinsaft","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2021092108265481400_pvaa096-B24","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jcmg.2011.03.017","article-title":"LV thrombus detection by routine echocardiography: insights into performance characteristics using delayed enhancement CMR","volume":"4","author":"Weinsaft","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"2021092108265481400_pvaa096-B25","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2021092108265481400_pvaa096-B26","doi-asserted-by":"crossref","first-page":"e0209187","DOI":"10.1371\/journal.pone.0209187","article-title":"Triple therapy after PCI\u2013warfarin treatment quality and bleeding risk","volume":"13","author":"Wadell","year":"2018","journal-title":"PLoS One"},{"key":"2021092108265481400_pvaa096-B27","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"2021092108265481400_pvaa096-B28","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"2021092108265481400_pvaa096-B29","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"2021092108265481400_pvaa096-B30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy: results from a Nationwide Danish Cohort Study","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"2021092108265481400_pvaa096-B31","first-page":"2324709617697991","article-title":"Rivaroxaban as an antithrombotic agent in a patient with ST-segment elevation myocardial infarction and left ventricular thrombus: a case report","volume":"5","author":"Seecheran","year":"2017","journal-title":"J Investig Med High Impact Case Rep"},{"key":"2021092108265481400_pvaa096-B32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00380-014-0562-z","article-title":"Successful resolution of a left ventricular thrombus with apixaban treatment following acute myocardial infarction","volume":"31","author":"Mano","year":"2016","journal-title":"Heart Vessels"},{"key":"2021092108265481400_pvaa096-B33","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2169\/internalmedicine.54.4191","article-title":"Effects of dabigatran on the resolution of left ventricular thrombus after acute myocardial infarction","volume":"54","author":"Ohashi","year":"2015","journal-title":"Intern Med"},{"key":"2021092108265481400_pvaa096-B34","doi-asserted-by":"crossref","first-page":"e14065","DOI":"10.1097\/MD.0000000000014065","article-title":"Resolution of left ventricular thrombus by edoxaban after failed treatment with warfarin overdose: a case report","volume":"98","author":"Kao","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2021092108265481400_pvaa096-B35","article-title":"Use of direct oral anticoagulants in the treatment of left ventricular thrombus: systematic review of current literature","author":"Kajy","year":"2019","journal-title":"Am J Ther"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaa096\/34111578\/pvaa096.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/5\/398\/40418792\/pvaa096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/5\/398\/40418792\/pvaa096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T04:29:36Z","timestamp":1632198576000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/7\/5\/398\/5878958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,7,30]]},"published-print":{"date-parts":[[2021,9,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa096","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9]]},"published":{"date-parts":[[2020,7,30]]}}}